tation, we attempted to define standards for scientific, research, and clinical practicality illustrating ideal or aspirational PRO measure development and implementation [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
PROs fROm ReseaRch tO PRactice tO POlicy: a fRamewORk
As a result of this review, we propose four stages that frame the translation of PROs from research to practice to policy ( Figure 1 ). Stage one, issue identification, is to ensure that PROs are targeting meaningful clinical areas and assessing domains of healthcare delivery that other quality metrics cannot, such as health-related quality of life and experience with care. As stakeholders continue to question whether PRO data is meaningful to both the patient and the provider, research and testing emerged as a key second step to make certain that a PRO measure is appropriate and usable to advance scientific knowledge. In the third phase, PRO measures in clinical practice will be able to predicate behavioral changes that drive quality improvement. And, if a PRO measure can successfully be implemented in clinical practice, then it can enter the final phase for implementation into quality and performance measurement. In this stage, measures are utilized to assess value from the patient's perspective in a way that is harmonized with PRO use in other settings. In designing this framework, one of the overarching aims was to identify and put forth opportunities for patient engagement in the research, care, and quality processes. The growing emphasis on patient centeredness suggests that the use of well-developed PRO measures can safeguard patients' needs and perspectives by assessing how treatment affects them. In research, FDA's Patient-Focused Drug Development (PFDD) provides patients with an opportunity to share input into clinical trial design and investment; the intROductiOn Despite a lack of consensus on what constitutes an ideal healthcare system, stakeholders have unanimously called for patient-centeredness as a national priority. In the midst of health reform, various health care entities (e.g. providers, hospitals, payers) have sought a deeper understanding of patient-reported outcomes (PROs), which reflect a patient's direct input in assessments of quality of life and value for a particular treatment. In recent years, there have been numerous efforts to integrate well-validated PROs into electronic health records, indicating growth in their importance [1] . Regardless of this interest and growth, several key gaps still remain in the development and routine use of PROs. For example, while PRO measures exist and are used in clinical trials, few are at the point of care in daily clinical practice, and even fewer are translated into quality and performance measures (tying payment to value in public and private programs in the U.S., Europe, and Canada). Furthermore, the PRO measures that do exist lack validation. Significant work needs to be done in order to incorporate greater input to measure self-reported health condition outcomes of greatest interest to the patient and account for gaps. One solution is a rigorous, step-wise, and nimble PRO development and translation approach that accommodates new information and best practices as they emerge [2] . In an effort to better understand the barriers around translation and conceptualize what exactly this nimble and step-wise process could resemble, we developed a translation framework to bridge the gap between integration of PROs into clinical trials and adoption into value-based reimbursement. Based on a survey of publicly-available literature from organizations that have historically had a role in PRO development and implemen-
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The authors have no conflicts of interest to declare. Using Patient-Reported Outcomes to include the patient in research, care, and quality use of PROs can help prioritize and capture endpoints that matter most to patients as well as enhance the benefit-risk assessment in regulatory decision making for biopharmaceutical products [15] . PROs can also heighten patient engagement in care processes, as they may provide guidance in determining patient health goals. Finally, robust PROs can support efforts to define value in the healthcare system more broadly and capture what is truly important to the patient. Avalere is neither the first, nor the last, stakeholder to dedicate time and thought to the issue of PRO translation from clinical trial to value-based reimbursement and the associated challenges. For example, the National Quality Forum (NQF) and the Patient-Centered Outcomes Research institute (PCORI) are focusing their efforts on the technical concerns related to the translation of PRO measures for use as performance measures [16] [17] [18] . Additionally, England's National Health Service has examined PRO measure data collection methods and associated opportunities to optimize patient response rates. In the context of this developing field, the stages identified in our framework put forward a process that begins to address some of the broader technical and methodological concerns with PRO translation. Increased attention on PRO translation is expected in the future; European countries have already made substantial progress towards the shift, and Health and Human Services (HHS) recently announced a goal of tying payment to value through alternative payment models and participation in reporting programs. The framework provides guidance on translating PROs from use to actual measurement that can be linked to payment.
cOnclusiOns
In the face of increased attention and activity around PRO translation, how can we ensure that patients are genuinely consulted and engaged throughout the PRO translation process? One possible place is determining whether patients are fully engaged throughout each of the four steps in our framework. For example, under the research and testing step, there is an opportunity for patients to play a role, thereby helping to determine if the PRO measure is fit for purpose. Still, though the framework provides a potential path forward in the PRO translation environment, considerable work still remains before such a framework can be implemented and adopted widely. Before we can move forward with entering measures through the framework, we must ensure that they are truly designed with the patient perspective in mind, and to that end, measure what matters most to patients: "Can I dance with my granddaughter at her wedding?" or "Will I be able to walk up the stairs?" Increasingly we are seeing interest in developing PRO measures with somewhat less quantifiable patient-reported outcomes (e.g., compassion, hope). With this careful attention to measure development comes a realization that, in some instances, the measures that matter to patients may not tient-centered efforts. While such efforts -our framework, included -are developed with the intent of placing patients at the center, there exists an opportunity to learn from best practices on how to execute on that vision and position ensure patients as partners throughout the development of patient-centered activities.
align with those that are of high priority for providers. We must reconcile this tension as we continue to shift towards a patient-centered healthcare system. Stakeholders looking at the big picture must continue to be thoughtful and deliberate in including patients in developing pa-
